Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant quality of life benefits for men with advanced prostate cancer

Trial Profile

Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant quality of life benefits for men with advanced prostate cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2007

At a glance

  • Drugs Bicalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top